INVEST IN IREMEDY
Invest in the Modern Medical Marketplace Disrupting the $130 Billion Medical Supply Industry
The medical supply chain is broken, and healthcare providers and patients are suffering as a result. We are on a mission to solve that problem by creating one of the world’s largest and most powerful procurement marketplaces — powered by our groundbreaking AI technology. We take the process of sourcing lifesaving supplies out of the hands of old, analog industry giants and put it into the hands of those who need it most.
MARKET LANDSCAPE
What Makes iRemedy Different From Others?
The medical supplies market is projected to reach $163.5 billion by 2027 from $138.4 billion in 2022, at a CAGR of 3.4% during the forecast period. The growth in this market is driven by the increasing demand for infection control measures to control hospital-acquired infections, increasing demand for medical devices, increasing number of ICU beds in hospitals and surgical centers, and rising number of accidents and trauma cases.
$138B+
USA MEDICAL SUPPLIES MARKET
5,000
HOSPITAL AND CARE ESTABLISHMENTS
9,750
SURGERY CENTERS
230,000
PHYSICIAN OFFICES
COMPETITIVE ADVANTAGE
The Medical Supply Industry
The typical medical supplier in the United States is over 100 years old. They were born before most homes had electricity and TVs, and before IBM built their first computer in 1953. And they still operate that way. We were born into a world that conquers complex problems with state-of-the-art, AI-driven technology. Our catalog is one of the largest, smartest public medical supply catalogs in the world, with over 500,000 products and growing. We solve complex pricing, contracting, and sourcing problems — automatically.
They are the past. We are the future.
THE PROBLEM
The Medical Supply Industry Is Broken
Over the past 40 years there has been frequent and dangerous shortages in drugs, supplies and devices needed for patients' health and welfare. Much of this problem was caused by a shift to overseas manufacturers and complicated by large, old, bureaucratic suppliers.
Hidden costs
Going with a legacy supplier means pricing fluctuations and tacked-on fees add up quickly, causing customers to dramatically overspend.
Global supply chain issues
It doesn’t take much disruption to upend global manufacturing and logistics, which causes massive shortages and disastrous delays. Today’s medical suppliers haven’t invested in the technology to track and predict these changes before they happen.
Negative customer experience
People expect a modern buying experience at home and at work. Only iRemedy simplifies complex medical supply purchasing through AI-powered user interface.
THE SOLUTION
Smart. American-based. Revolutionary.
Patients and healthcare providers deserve the peace of mind that comes from knowing they have what they need, when they need it most. They deserve to reach their health goals. They deserve to offer patients the best care possible. That’s where iRemedy comes in.
Transparent pricing
No hidden costs or fees. No surprises. Just the best price available for the products you need.
Easy ordering
Simple, fast, and secure. Our interface is user-friendly and direct — what you see is what you get. We manage multiple suppliers, and contracts in a 'one stop shop'..
Constant supply monitoring
iRemedy uses groundbreaking AI to track inventories, shipments, and manufacturers 24/7. Customers can easily stay aware of shortages, so they don’t waste valuable time and money.
90% of All Medical Supplies are Sourced in Asia
iRemedy's mission is to focus on more domestic supply and a more resilient global supply chain.
The Time For Change is Now.
There’s never been a better time to empower patients and healthcare providers with a service that will not only make their lives easier but will literally save lives. When you invest in iRemedy, you’re investing in the future of healthcare — an industry desperate for modernization. Be a part of this incredible technology-fueled step forward. Join our growing community of investors today.
OPPORTUNITY
COMPETITIVE ADVANTAGE
Revolutionize the Broken and Corrupt Medical Industry With Us
Having access to medical supplies can be an issue of life or death. Waiting is not an option, and going through red tape only makes helping people harder. The medical supply industry is failing patients. iRemedy is a disruptive solution that can transform the industry. Our catalog is one of the largest, smartest public medical supply catalog in the world, with over 500,000 products and growing. We solve complex pricing, contracting, and sourcing problems — automatically. The gold standard is here, and it’s going to change everything.
THE TEAM
Executive Leadership Team
iRemedy has assembled the best of the best for a winning team. From Microsoft to Amazon, to multiple successful exits, the iRemedy team is positioned to continue to grow this multi-million dollar company into a medical supply giant.
Tony Paquin
Co-Founder, President and Chief Executive Officer
Jim Harding
Chief Technology Officer
IREMEDY REVENUE
iRemedy Revenue
REVENUE
$ 52,104,276
SIMPLE STEPS TO PURCHASE MEDICAL SUPPLIES
A Better Solution for a Modern World
Medical supply purchasing has become unnecessarily complex and unreliable. For consumers at home and professionals at work, a more modern, intelligent, and user friendly solution is needed. iRemedy delivers on that promise.
We have over 500,000 products in our catalog, and our platform constantly monitors pricing and availability.
BROWSE
Medical products have complex rules about pricing, GPO contracts, availability, allocations, and licensing requirements. We analyze millions of data points to be sure our clients get the right product at the right price.
SOURCE
Medical products have complex rules about pricing, GPO contracts, availability, allocations, and licensing requirements. We analyze millions of data points to be sure you get the right product, at the best possible price for you — every time you buy.
ANALYZE
With a simple click, you can buy a product for your personal use or manage the purchase of tens of thousands of products for hundreds of locations. Fast, easy, and modern — just as you would expect.
After the purchase, we help our professional clients analyze cost and availability. We manage clinical preferences, contract compliance, distributor margins, and buyer activities – on their behalf and all automatically. Our AI is generating the intelligence our clients need to ensure they succeed in their mission.
PURCHASE
REPORT
JOIN TODAY AND MAKE A CHANGE
Invest in iRemedy
iRemedy will soon change forever the way medical supplies are sourced in the United States. Confusing prices, product shortages, and outrageous costs will be a thing of the past as we modernize the supply chain with artificial intelligence.
THESE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARDLOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS. PLEASE NOTE INVESTORS IN THIS OFFERING WILL BE CLIENTS OF THE ISSUER AND NOT DALMORE GROUP, LLC (“DALMORE”), A REGISTERED BROKER-DEALER AND MEMBER FINRA/SIPC. DALMORE’S ROLE IN THE TRANSACTION IS TO FACILITATE BACK OFFICE AND REGULATORY FUNCTIONS RELATED TO THE REGULATION A TRANSACTION, AND ACTS ONLY AS THE BROKER/DEALER OF RECORD FOR THE OFFERING LISTED. DALMORE IS NOT PROVIDING INVESTMENT ADVICE OR RECOMMENDATIONS, OR LEGAL OR TAX ADVICE. NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. YOU MAY OBTAIN A COPY OF THE PRELIMINARY OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED By: JT Sadler Feb 03 2023 CRD: 2817763 BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AT: http://edgar.secdatabase.com/1886/190359623000098/filing-main.htm
IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. REGULATION A OFFERINGS ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.
7118 S. Kanner Hwy
Stuart, FL 34997
customerservice@iRemedy.com
(855) 889-6869
iRemedy Innovations is offering securities through the use of an Offering Statement that the Securities and Exchange Commission (‘SEC”) has qualified under Tier II of Regulation A. While the SEC staff reviews certain forms and filings for compliance with disclosure obligations, the SEC does not evaluate the merits of any offering, nor does it determine if any securities offered are “good” investments.
iRemedy Innovations (“iRemedy Innovations”) is registered with the Securities and Exchange Commission (“SEC”) as a broker-dealer, member of Financial Industry Regulatory Authority, Inc. (“FINRA”) and Securities Investor Protection Corporation (“SIPC”) and is the broker-dealer of record on this issuer direct offering.
COPYRIGHT © 2022 IREMEDY ALL RIGHTS RESERVED
